Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
242.61
+0.64 (0.26%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Alnylam Pharmaceuticals Revenue
In the year 2024, Alnylam Pharmaceuticals had annual revenue of $2.25B with 22.97% growth. Alnylam Pharmaceuticals had revenue of $593.17M in the quarter ending December 31, 2024, with 34.90% growth.
Revenue (ttm)
$2.25B
Revenue Growth
+22.97%
P/S Ratio
13.77
Revenue / Employee
$1,070,592
Employees
2,100
Market Cap
31.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 419.95M | 22.97% |
| Dec 31, 2023 | 1.83B | 790.87M | 76.23% |
| Dec 31, 2022 | 1.04B | 193.13M | 22.88% |
| Dec 31, 2021 | 844.29M | 351.43M | 71.31% |
| Dec 31, 2020 | 492.85M | 273.10M | 124.28% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
ALNY News
- 7 days ago - Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results - Business Wire
- 23 days ago - Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference - Business Wire
- 26 days ago - Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 - Business Wire
- 27 days ago - FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B - Business Wire
- 4 weeks ago - siRNA Gene Silencing Market Landscape Report 2025: United States and Ireland Stand Out with 2 Major M&A Deals Worth $54.9 Billion, Alnylam Pharmaceuticals Leads the Way with 79 Trials - GlobeNewsWire
- 4 weeks ago - Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock - Benzinga
- 4 weeks ago - Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster - Seeking Alpha
- 4 weeks ago - Alnylam's Amvuttra Secures FDA Approval For Expanded Use For Rare Heart Disease, Stock Jumps - Benzinga